中富通(300560) - 2024 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2024 was ¥367,068,064.30, representing a 26.60% increase compared to ¥289,946,289.07 in the same period last year[4] - Net profit attributable to shareholders decreased by 28.12% to ¥10,919,621.90 from ¥15,192,356.22 year-on-year[4] - Total operating revenue for the first quarter was ¥367,068,064.30, an increase of 26.5% compared to ¥289,946,289.07 in the previous period[23] - Net profit for the quarter was ¥9,816,518.70, a decrease of 37.1% from ¥15,571,034.93 year-over-year[24] - Basic earnings per share were ¥0.0475, down from ¥0.0667 in the previous period[24] - The company reported a total comprehensive income of ¥9,647,060.72, down from ¥15,547,225.81 in the previous year[24] Cash Flow and Operating Activities - The net cash flow from operating activities improved by 67.53%, reaching -¥29,742,257.38 compared to -¥91,602,614.23 in the previous year[4] - Cash flow from operating activities showed a net outflow of ¥29,742,257.38, an improvement from a net outflow of ¥91,602,614.23 in the same period last year[26] - Cash and cash equivalents at the end of the period were ¥235,886,601.32, down from ¥311,186,613.75 at the end of the previous period[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,728,365,782.62, a slight increase of 0.22% from ¥2,722,441,098.83 at the end of the previous year[5] - The company's total liabilities decreased from CNY 1,622,354,813.22 to CNY 1,618,632,436.29 during the same period[21] - The total equity attributable to shareholders increased from CNY 1,077,027,150.43 to CNY 1,087,777,314.35, reflecting a growth of approximately 1.3%[21] - Cash and cash equivalents decreased from CNY 753,487,937.63 to CNY 661,423,627.42, a decline of about 12.2%[19] - Accounts receivable slightly decreased from CNY 1,081,482,120.28 to CNY 1,060,193,678.42, a reduction of approximately 2%[19] Research and Development - The company's R&D expenditures increased significantly by 451.19% to ¥10,944,400.00, driven by ongoing investments in research projects[9] - Research and development expenses increased to ¥14,821,831.76, compared to ¥11,561,220.19 in the prior period, reflecting a focus on innovation[23] Financial Performance and Expenses - Financial expenses rose by 188.52% to ¥6,956,100.00, primarily due to a significant decrease in exchange gains compared to the previous year[10] - Other income decreased by 35.46% to ¥1,570,900.00, mainly due to reduced government subsidies received during the reporting period[10] - The weighted average return on equity was 1.00%, down from 1.30% in the same period last year, reflecting a decline of 0.30%[4] - The company incurred credit impairment losses of ¥5,960,174.38, compared to ¥2,927,589.91 in the previous period, indicating increased risk[24] Shareholder Information and Incentives - The number of ordinary shareholders at the end of the reporting period was 22,883, with the largest shareholder holding 24.82% of the shares[13] - The company plans to grant 1,650,000 restricted shares at a price of CNY 12.80 per share as part of its 2024 stock incentive plan[18] - The number of core management and key employees involved in the stock incentive plan is 93[18] - The company reported a total of CNY 150,000,000 in restricted shares to be granted initially, with an additional 150,000 shares reserved[18] Investments and Borrowings - The company's long-term investments increased from CNY 7,550,618.30 to CNY 7,626,524.92, indicating a growth of approximately 1%[20] - The company's short-term borrowings rose from CNY 590,637,683.74 to CNY 616,639,127.74, an increase of about 4.4%[20] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24]